Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Key Points

• Kiniksa Pharmaceuticals reported a quarterly EPS of $0.23, significantly surpassing analysts' expectations of $0.08.
• Insider trading showed notable activity, with Ross Moat and Barry D. Quart selling substantial amounts of shares, indicating a 74.56% and 49.58% decrease in their holdings, respectively.
• Several analysts have increased their price targets for Kiniksa's shares, with Jefferies Financial Group setting a new objective at $45.00, reflecting strong confidence in the company's performance.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05, Zacks reports. Kiniksa Pharmaceuticals International had a return on equity of 1.08% and a net margin of 0.90%. The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International updated its FY 2025 guidance to EPS.

Kiniksa Pharmaceuticals International Trading Down 1.0%

KNSA stock traded down $0.31 during midday trading on Wednesday, hitting $30.06. The stock had a trading volume of 1,224,939 shares, compared to its average volume of 594,751. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of 751.69 and a beta of 0.05. The stock has a 50-day simple moving average of $28.19 and a 200 day simple moving average of $23.89. Kiniksa Pharmaceuticals International has a 52 week low of $17.82 and a 52 week high of $31.92.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 17,647 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $26.69, for a total transaction of $470,998.43. Following the completion of the transaction, the chief accounting officer directly owned 32,546 shares of the company's stock, valued at approximately $868,652.74. This trade represents a 35.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ross Moat sold 27,594 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total value of $800,777.88. Following the completion of the sale, the insider owned 9,415 shares of the company's stock, valued at approximately $273,223.30. This trade represents a 74.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 344,215 shares of company stock valued at $9,840,484. Insiders own 53.48% of the company's stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently made changes to their positions in the business. Amundi acquired a new stake in Kiniksa Pharmaceuticals International in the first quarter worth about $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock worth $507,000 after purchasing an additional 1,002 shares during the period. Finally, Millennium Management LLC increased its position in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock worth $18,815,000 after purchasing an additional 67,452 shares during the period. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday, July 6th. Wedbush reiterated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Finally, Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.